ALIMERA SCIENCES INC (ALIM)
US0162592028 - Common Stock
Overall ALIM gets a fundamental rating of 3 out of 10. We evaluated ALIM against 198 industry peers in the Pharmaceuticals industry. ALIM may be in some trouble as it scores bad on both profitability and health. ALIM is valued quite expensive, but it does show an excellent growth.
1. Profitability
1.1 Basic Checks
ALIM had negative earnings in the past year.
ALIM had a negative operating cash flow in the past year.
In the past 5 years ALIM always reported negative net income.
ALIM had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
The Return On Assets of ALIM (-13.93%) is better than 68.72% of its industry peers.
The Return On Equity of ALIM (-46.33%) is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.93% | ||
| ROE | -46.33% | ||
| ROIC | N/A |
ROA(3y)-21.3%
ROA(5y)-19.03%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
ALIM has a better Gross Margin (86.57%) than 89.74% of its industry peers.
ALIM's Gross Margin has been stable in the last couple of years.
ALIM does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.57% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y0.09%
GM growth 5Y-0.94%
2. Health
2.1 Basic Checks
ALIM does not have a ROIC to compare to the WACC, probably because it is not profitable.
ALIM has more shares outstanding than it did 1 year ago.
ALIM has more shares outstanding than it did 5 years ago.
ALIM has a better debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -1.99, we must say that ALIM is in the distress zone and has some risk of bankruptcy.
ALIM has a Altman-Z score of -1.99. This is comparable to the rest of the industry: ALIM outperforms 46.15% of its industry peers.
ALIM has a Debt/Equity ratio of 1.40. This is a high value indicating a heavy dependency on external financing.
ALIM has a worse Debt to Equity ratio (1.40) than 78.46% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.4 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -1.99 |
ROIC/WACCN/A
WACC9.6%
2.3 Liquidity
A Current Ratio of 2.39 indicates that ALIM has no problem at all paying its short term obligations.
With a Current ratio value of 2.39, ALIM is not doing good in the industry: 60.51% of the companies in the same industry are doing better.
A Quick Ratio of 2.31 indicates that ALIM has no problem at all paying its short term obligations.
With a Quick ratio value of 2.31, ALIM perfoms like the industry average, outperforming 43.59% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.31 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 16.60% over the past year.
Looking at the last year, ALIM shows a very strong growth in Revenue. The Revenue has grown by 49.20%.
ALIM shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 11.62% yearly.
EPS 1Y (TTM)16.6%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q87.04%
Revenue 1Y (TTM)49.2%
Revenue growth 3Y16.69%
Revenue growth 5Y11.62%
Revenue growth Q2Q87.5%
3.2 Future
The Earnings Per Share is expected to grow by 22.39% on average over the next years. This is a very strong growth
Based on estimates for the next years, ALIM will show a very strong growth in Revenue. The Revenue will grow by 23.40% on average per year.
EPS Next Y97.48%
EPS Next 2Y43.58%
EPS Next 3Y29.75%
EPS Next 5Y22.39%
Revenue Next Year31.61%
Revenue Next 2Y22.73%
Revenue Next 3Y19.82%
Revenue Next 5Y23.4%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings Ratio is negative for ALIM. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for ALIM. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
Based on the Enterprise Value to EBITDA ratio, ALIM is valued a bit cheaper than the industry average as 77.44% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | 35.76 |
4.3 Compensation for Growth
ALIM's earnings are expected to grow with 29.75% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y43.58%
EPS Next 3Y29.75%
5. Dividend
5.1 Amount
No dividends for ALIM!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
ALIMERA SCIENCES INC
NASDAQ:ALIM (5/3/2024, 7:00:00 PM)
3.65
+0.17 (+4.89%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap191.08M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -13.93% | ||
| ROE | -46.33% | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 86.57% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover0.53
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 1.4 | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 2.39 | ||
| Quick Ratio | 2.31 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)16.6%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y97.48%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)49.2%
Revenue growth 3Y16.69%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y